Covetrus issued a public statement saying it will defend its proposed merger with MWI Animal Health in court rather than abandon the deal after the Federal Trade Commission filed suit to block it.
According the statement, the distributor argues the FTC's antitrust case relies on a "narrow and outdated view" of the veterinary supply chain. The company claims clinics routinely use multiple purchasing channels to maintain competitive pricing, not single distributors.
The alternative channels Covetrus says the FTC ignored
To illustrate what it calls actual market dynamics, Covetrus' statement highlighted several purchasing avenues beyond the two major distributors.
The company stated that competition from these sources has "consistently pushed prices down for clinics," a reality it claims will remain unaffected by the proposed merger.
What this means for contract negotiations
A court fight means uncertainty while the case plays out. Owner-DVMs negotiating a supply contract with either Covetrus or MWI are doing it while both companies are in litigation over whether they'll be one entity or two.
That uncertainty changes the leverage calculation on whether to split purchasing between vendors or consolidate with one, but neither side can say yet how it resolves.
If the merger is blocked, the current structure holds. If Covetrus wins, the pricing pressure from the "multiple channels" the company cited in its defense will be tested in the market.
If your practice buys through a distributor, this case determines your contract options. subscribe to VeterinaryPracticeNow.
Our read on the defense strategy
Covetrus is arguing the court should accept a broader definition of the market than the FTC used. The company is arguing the real market includes alternative purchasing channels that compete on price.
That's a standard merger-defense move, and whether it works depends on how the court weighs convenience against price. A clinic can buy some products through alternative channels, but the court will decide whether those alternatives are real competitive pressure or just edge cases that don't constrain distributor pricing for the bulk of what a clinic buys.
The company's claim that competition has "consistently pushed prices down" is an assertion, not a data point. The court case will turn on what evidence Covetrus can produce to support it.
We'd watch for what the actual pricing data shows when it comes out in court. That number will matter more than the statement.